DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Mavik (Trandolapril) - Published Studies

 
 



Mavik Related Published Studies

Well-designed clinical trials related to Mavik (Trandolapril)

Trandolapril, but not verapamil nor their association, restores the physiological renal hemodynamic response to adrenergic activation in essential hypertension. [2011.06]

Effects of verapamil added-on trandolapril therapy in hypertensive type 2 diabetes patients with microalbuminuria: the BENEDICT-B randomized trial. [2011.02]

Genetic variation in the beta2 subunit of the voltage-gated calcium channel and pharmacogenetic association with adverse cardiovascular outcomes in the INternational VErapamil SR-Trandolapril STudy GENEtic Substudy (INVEST-GENES). [2010.12]

Coronary revascularization strategy and outcomes according to blood pressure (from the International Verapamil SR-Trandolapril Study [INVEST]). [2010.08.15]

Changes of matrix metalloproteinase-9 level is associated with left ventricular remodeling following acute myocardial infarction among patients treated with trandolapril, valsartan or both. [2010.06]

Changes of matrix metalloproteinase-9 level is associated with left ventricular remodeling following acute myocardial infarction among patients treated with trandolapril, valsartan or both. [2010.05.25]

Effect of verapamil, trandolapril and their combination on vascular function and structure in essential hypertensive patients. [2009.07]

Pulse pressure and risk of cardiovascular outcomes in patients with hypertension and coronary artery disease: an INternational VErapamil SR-trandolapril STudy (INVEST) analysis. [2009.06]

Alpha-adducin polymorphism associated with increased risk of adverse cardiovascular outcomes: results from GENEtic Substudy of the INternational VErapamil SR-trandolapril STudy (INVEST-GENES). [2008.08]

Verapamil-sustained release-based treatment strategy is equivalent to atenolol-based treatment strategy at reducing cardiovascular events in patients with prior myocardial infarction: an INternational VErapamil SR-Trandolapril (INVEST) substudy. [2008.08]

Blood pressure control and improved cardiovascular outcomes in the International Verapamil SR-Trandolapril Study. [2007.08]

Factors influencing blood pressure response to trandolapril add-on therapy in patients taking verapamil SR (from the International Verapamil SR/Trandolapril [INVEST] Study). [2007.06.01]

Antihypertensive properties of a high-dose combination of trandolapril and verapamil-SR. [2007.03.01]

Antihypertensive properties of a high-dose combination of trandolapril and verapamil-SR. [2007.03]

Predictors of development of diabetes mellitus in patients with coronary artery disease taking antihypertensive medications (findings from the INternational VErapamil SR-Trandolapril STudy [INVEST]). [2006.10.01]

Efficacy and tolerability of trandolapril in mild to moderate hypertension--a double blind comparative clinical trial with enalapril in Indian population. [2006.10]

Global differences in blood pressure control and clinical outcomes in the INternational VErapamil SR-Trandolapril STudy (INVEST). [2005.07]

Low doses of losartan and trandolapril improve arterial stiffness in hemodialysis patients. [2005.05]

Comparison of suppression of the circulating and vascular renin-angiotensin system by enalapril versus trandolapril in chronic heart failure. [2004.12.15]

Effects of combination treatment with losartan and trandolapril on office and ambulatory blood pressures in non-diabetic renal disease: a COOPERATE-ABP substudy. [2004.09]

The effect of trandolapril and its fixed-dose combination with verapamil on proteinuria in normotensive adults with type 2 diabetes. [2004.07]

Effects of bedtime vs. morning administration of the long-acting lipophilic angiotensin-converting enzyme inhibitor trandolapril on morning blood pressure in hypertensive patients. [2004.01]

A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial. [2003.12.03]

The angiotensin converting enzyme inhibitor trandolapril has neutral effect on exercise tolerance or functional class in patients with myocardial infarction and reduced left ventricular systolic function. [2003.12]

The verapamil versus amlodipine in nondiabetic nephropathies treated with trandolapril (VVANNTT) study. [2003.07]

Antihypertensive therapy with verapamil SR plus trandolapril versus atenolol plus chlorthalidone on glycemic control. [2003.05]

Time-effect profile of antihypertensive agents assessed with trough/peak ratio, smoothness index and dose omission: an ambulatory blood pressure monitoring study with trandolapril vs. quinapril. [2002.12]

Cardiac autonomic tone during trandolapril-irbesartan low-dose combined therapy in hypertension: a pilot project. [2002.08]

Acute blood pressure response to trandolapril and captopril in patients with left ventricular dysfunction after acute myocardial infarction. [2002.02]

Verapamil versus amlodipine in proteinuric non-diabetic nephropathies treated with trandolapril (VVANNTT study): design of a prospective randomized multicenter trial. [2001.01]

Early neurohormonal effects of trandolapril in patients with left ventricular dysfunction and a recent acute myocardial infarction: a double-blind, randomized, placebo-controlled multicentre study. [2001.01]

Evaluation of the effects of fixed combinations of sustained-release verapamil/trandolapril versus captopril/hydrochlorothiazide on metabolic and electrolyte parameters in patients with essential hypertension. [2000.06]

Induction of insulin resistance by beta-blockade but not ACE-inhibition: long-term treatment with atenolol or trandolapril. [2000.03]

Insulin sensitivity in hypertensive Type 2 diabetic patients after 1 and 19 days' treatment with trandolapril. [2000.02]

Efficacy and safety of a new long-acting drug combination, trandolapril/verapamil as compared to monotherapy in primary hypertension. Swedish TARKA trialists. [2000]

Trandolapril reduces the incidence of atrial fibrillation after acute myocardial infarction in patients with left ventricular dysfunction. [1999.07.27]

Effect of ACE inhibitor trandolapril on life expectancy of patients with reduced left-ventricular function after acute myocardial infarction. TRACE Study Group. Trandolapril Cardiac Evaluation. [1999.07.03]

Effect of the angiotensin-converting enzyme inhibitor trandolapril on mortality and morbidity in diabetic patients with left ventricular dysfunction after acute myocardial infarction. Trace Study Group. [1999.07]

Brazilian multicenter study on efficacy and tolerability of trandolapril in mild-to-moderate essential arterial hypertension. EMBATHE substudy with ambulatory blood pressure monitoring. [1999.05]

Changes in arterial structure and function under trandolapril-verapamil combination in hypertension. [1999.05]

Long-term prognostic importance of hyperkinesia following acute myocardial infarction. TRACE Study Group. TRAndolapril Cardiac Evaluation. [1999.03.01]

Controlled study of the effect of angiotensin converting enzyme inhibition versus calcium-entry blockade on insulin sensitivity in overweight hypertensive patients: Trandolapril Italian Study (TRIS). [1999.03]

Antiproteinuric efficacy of verapamil in comparison to trandolapril in non-diabetic renal disease. [1999.01]

Effect of angiotensin-converting-enzyme (ACE) inhibitor trandolapril on human diabetic neuropathy: randomised double-blind controlled trial. [1998.12.19]

Failure of an ACE inhibitor to improve exercise tolerance. A randomized study of trandolapril. Trandolapril study group. [1998.12]

Rationale and design of the International Verapamil SR/Trandolapril Study (INVEST): an Internet-based randomized trial in coronary artery disease patients with hypertension. [1998.11]

Blood pressure and aortic elastic properties--verapamil SR/trandolapril compared to a metoprolol/hydrochlorothiazide combination therapy. [1998.08]

Verapamil SR and trandolapril combination therapy in hypertension--a clinical trial of factorial design. German Hypertension Study Group. [1998.05]

Renin status does not predict the anti-hypertensive response to angiotensin-converting enzyme inhibition in African-Americans. Trandolapril Multicenter Study Group. [1998.03]

Effects of verapamil and trandolapril in the treatment of hypertension. Trandolapril Study Group. [1998.03]

Congestive heart failure and ischaemic heart disease treated with trandolapril and verapamil. DAVIT Study Group. Danish Verapamil Infarction Trial. [1998.01]

Influence of a history of arterial hypertension and pretreatment blood pressure on the effect of angiotensin converting enzyme inhibition after acute myocardial infarction. Trandolapril Cardiac Evaluation Study. [1998.01]

Treatment with verapamil and trandolapril in patients with congestive heart failure and angina pectoris or myocardial infarction. The DAVIT Study Group. Danish Verapamil Infarction Trial. [1997.08]

Do trandolapril and indomethacin influence renal function and renal functional reserve in hypertensive patients? [1997.08]

Fixed-dose combination therapy with trandolapril and verapamil SR is effective in primary hypertension. Trandolapril Study Group. [1997.07]

Effect of angiotensin converting enzyme inhibition after acute myocardial infarction in patients with arterial hypertension. TRACE Study Group, Trandolapril Cardiac Event. [1997.07]

[Demonstration of differences in the effect of 2 antihypertensive agents by self blood pressure measurement: comparison of trandolapril and perindopril] [1997.05]

Efficacy of combination therapy with trandolapril and verapamil sr in primary hypertension: a 4 x 4 trial design. The Trandolapril Study Group. [1997.04]

Cardiac event rates after acute myocardial infarction in patients treated with verapamil and trandolapril versus trandolapril alone. Danish Verapamil Infarction Trial (DAVIT) Study Group. [1997.03.15]

Indomethacin does not attenuate the hypotensive effect of trandolapril. [1996.11]

[Trandolapril in patients with left ventricular insufficiency after myocardial infarction] [1996.08]

Angiotensin-converting enzyme inhibition after myocardial infarction: the Trandolapril Cardiac Evaluation Study. [1996.07]

Metabolic neutrality of combined verapamil-trandolapril treatment in contrast to beta-blocker-low-dose chlortalidone treatment in hypertensive type 2 diabetes. [1996.05]

Once-daily monotherapy with trandolapril in the treatment of hypertension. [1996.02]

Antihypertensive effects of trandolapril and nitrendipine in the elderly: a controlled trial with special emphasis on time effect profiles. [1996.01]

A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. Trandolapril Cardiac Evaluation (TRACE) Study Group. [1995.12.21]

Permanent blood pressure control over the 24 h by trandolapril. [1995.10]

Multiple doses of trandolapril do not affect warfarin pharmacodynamics. [1995.08]

Differing mechanisms of action of angiotensin-converting enzyme inhibition in black and white hypertensive patients. The Trandolapril Multicenter Study Group. [1995.07]

Differential effects of a missed dose of trandolapril and enalapril on blood pressure control in hypertensive patients. [1995.07]

Comparison of the efficacy and safety of trandolapril and nifedipine SR in mild-to-moderate hypertension. Investigator Study Group. [1994]

Double-blind comparison of the efficacy and safety of trandolapril 2 mg and hydrochlorothiazide 25 mg in patients with mild-to-moderate essential hypertension. Investigator Study Group. [1994]

Comparison of the efficacy and safety of trandolapril and captopril for 16 weeks in mild-to-moderate essential hypertension. Investigator Study Group. [1994]

Effects of trandolapril on 24-h ambulatory blood pressure in patients with mild-to-moderate essential hypertension. [1994]

Efficacy and tolerance of trandolapril (0.5-2 mg) administered for 4 weeks in patients with mild-to-moderate hypertension. Investigator Study Group. [1994]

Trandolapril: pharmacokinetics of single oral doses in healthy male volunteers. [1994]

Once-daily trandolapril compared with the twice-daily formulation in the treatment of mild to moderate essential hypertension: assessment by conventional and ambulatory blood pressures. [1993.09]

Evaluation of the antihypertensive effect of once-a-day trandolapril by 24-hour ambulatory blood pressure monitoring. The Italian Trandolapril Study Group. [1992.10.29]

Absence of potentiation of the skin response to intradermal bradykinin by a long-acting angiotensin converting enzyme inhibitor, trandolapril, at conventional antihypertensive dosage in human volunteers: a double-blind, randomized, cross-over, placebo-controlled trial. [1992.09]

Effects of the converting enzyme inhibitor trandolapril on short-term variability of blood pressure in essential hypertension. [1991.12]

Safety and tolerance of single oral doses of trandolapril (RU 44.570), a new angiotensin converting enzyme inhibitor. [1989]

Well-designed clinical trials possibly related to Mavik (Trandolapril)

Plasma sodium and mortality risk in patients with myocardial infarction and a low LVEF. [2011.11]

Prognostic utility of secretory phospholipase A(2) in patients with stable coronary artery disease. [2011.09]

Target blood pressure in diabetes patients with hypertension--what is the accumulated evidence in 2011? [2011.08]

Preserved or slightly depressed ejection fraction and outcomes after myocardial infarction. [2011.06]

Chromosome 9p21 haplotypes and prognosis in white and black patients with coronary artery disease. [2011.04]

Prognostic utility of secretory phospholipase A(2) in patients with stable coronary artery disease. [2011]

Blood pressure and outcomes in very old hypertensive coronary artery disease patients: an INVEST substudy. [2010.08]

Systolic blood pressure and subjective well-being in patients with coronary artery disease. [2009.11]

Bedtime versus at awakening administration of BP lowering drugs--is it the way to success? [2009]

Effects of calcium channel blockers on proteinuria in patients with diabetic nephropathy. [2008.10]

Reversal of diuretic-associated impaired glucose tolerance and new-onset diabetes: results of the STAR-LET study. [2008.01]

Comparison of high- versus low-tissue affinity ACE-inhibitor treatment on circulating aldosterone levels in patients with chronic heart failure. [2007.12]

Prognostic value of B-Type natriuretic peptides in patients with stable coronary artery disease: the PEACE Trial. [2007.07.17]

Optimal treatment of obesity-related hypertension: the Hypertension-Obesity-Sibutramine (HOS) study. [2007.04.17]

Prognostic significance of the Centers for Disease Control/American Heart Association high-sensitivity C-reactive protein cut points for cardiovascular and other outcomes in patients with stable coronary artery disease. [2007.03.27]

Association of CYP3A5 polymorphisms with hypertension and antihypertensive response to verapamil. [2007.03]

[Antiatherogenic effects of Angiotensin converting enzyme inhibitors from the point of view of evidence based medicine.] [2007]

Dual therapy in hypertensive patients with coronary artery disease: the role of calcium channel blockers and beta-blockers. [2007]

Renal function and effectiveness of angiotensin-converting enzyme inhibitor therapy in patients with chronic stable coronary disease in the Prevention of Events with ACE inhibition (PEACE) trial. [2006.07.04]

Dogma disputed: can aggressively lowering blood pressure in hypertensive patients with coronary artery disease be dangerous? [2006.06.20]

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017